Cipla Limited announced a significant expansion of its manufacturing facility located at Innovation Way in Fall River, Massachusetts. This expansion includes an 83,000-square-foot addition to the existing facility, aimed at increasing production capacity and enhancing operational efficiency. Cipla is expanding its US manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, MA & Central Islip, Long Island NY.
The new facility will feature state-of-the-art technology and advanced manufacturing processes, ensuring the highest standards of quality and efficiency. Cipla's facility is dedicated to the production of respiratory products for the US market. This facility possesses comprehensive filling capabilities, stringent quality assurance processes, and a specialized workforce trained in complex manufacturing. These capabilities highlight Cipla's commitment to delivering high-quality respiratory care solutions and serving patients across the country.
Marc Falkin, CEO, Cipla North America, said, "This expansion not only underscores our commitment to manufacturing generic pharmaceuticals in the US market, but also reflects our dedication to supporting the community through job creation and economic development."
Comments powered by CComment